Medicines that carry warnings about sleep disturbances do not seem to contribute to the amount of sleep disturbances in the general population, according to new ‘real world’ research. The findings, which are published in the British Journal of Clinical Pharmacology suggest that investigators may need to provide more careful reporting of side effects in clinical trials, and emphasizes the value of research into the safety of medicines once they are being taken by the general population.
Sleep disturbances and their consequences can have considerable impacts on health. Drugs are labelled as sleep disturbing in patient information leaflets due to findings from clinical trials, but it’s unclear whether these drugs actually lead to more sleep disorders—such as difficulties falling or staying asleep, or waking in the early morning—in the general population. To investigate Anna-Therese Lehnich, of the University of Duisburg-Essen in Germany, and her colleagues analysed information on 4,221 individuals aged 45 to 75 years.
Interviews revealed no clear links between drugs labelled as sleep disturbing with actual experiences of problems related to sleep. “We found that drugs labelled as sleep disturbing do not contribute strongly to the high frequency of sleep disturbances in the general population. Moreover, the intake of several sleep disturbing drugs at the same time barely led to more sleep disturbances at night,” said Lehnich. “Surprisingly, we could not show that the frequency categories—‘uncommon,’ ‘common,’ and ‘very common’—for the occurrence of sleep disturbances from patient information leaflets result in different frequencies of sleep disturbances.”
